Research Study: COVID PACT
Condition:
COVID-19
Study Sponsor: Critical Care Cardiology Trials Network (CCCTN)
Study Investigator: Retu Saxena, MD
Study Contact: Irena Davies
irena.davies@allina.com
612-863-4393
Every research study comes with its own unique risks and benefits; the study team will assess whether you’re an eligible candidate and ensure you’re provided with all the information you need to decide if participating is right for you.
About this Study:

This is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events.
Eligibility Criteria:

  • Age ≥18 years (male or female)
  • Acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)
  • Currently admitted to an intensive care unit (ICU)

Interested in participating in this study?

Reach out to the study contact directly, or fill out this form and we will contact you and assess whether you are an eligible candidate!